
|Articles|July 26, 2002
Flexible light-based system gets FDA nod
TheraLight received clearance from the U.S. Food and Drug Administrationto market its UV120-2 UVA/UUVB Phototherapy System for the treatment ofpsoriasis, vitiligo, atopic dermatitis and seborrheic dermatitis.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Transformative Advances This Year and Beyond
2
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
3
Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control
4
"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions
5


















